Heat Biologics (HTBX) Suspends Proposed Offering of Common Stock; to Explore Alternative Options
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- JPMorgan (JPM) Reports a Q1 Beat on Revenue and Profit Fueled by Release of $5.2 Billion Reserved for Bad Loans; Shares Slightly Down
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company has suspended the proposed public offering of shares of its common stock previously announced on July 21, 2016. Heat’s leadership team decided to suspend the proposed public offering to explore alternative options presented to the company.
As previously reported, Heat had cash, cash equivalents and short-term investments totaling approximately $11.8 million as of March 31, 2016. The company continues to expect to achieve near-term clinical milestones for its two product candidates with its current cash on-hand. Topline data for both clinical programs, including Heat’s lead Phase 2 HS-410 non-muscle invasive bladder cancer program, are expected in the fourth quarter of 2016.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Maxeon (MAXN) Announces $125M Public Offering of Ordinary Shares
- Heat Biologics (HTBX) Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research
- Costar Group (CSGP) Reports Acquisition of Homes.com for $156M from Dominion Enterprises
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, Hot Corp. News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!